Archive · 3 Jul 2025
FDA Vaccine Chief Limits COVID Shot Use, Overruling Staff
The head of vaccines at the FDA, Dr. Prasad, changed the rules for two COVID-19 vaccines, even though the scientists working under him had already said they were safe.
Originally, the scientists wanted everyone 12 and older to be able to get the shots, but Dr. Prasad said they should only be given to people who are more likely to get very sick from COVID, like older adults or people with other health problems.
He made this decision because fewer people are dying or going to the hospital from COVID, and he was worried about rare side effects from the vaccines.
This kind of decision is unusual for top FDA officials.
FDA vaccine chief, Dr. Vinay Prasad, restricted COVID-19 vaccine approval, overriding staff recommendations.
The restrictions apply to Novavax and Moderna vaccines, initially approved for those 12 and older.
Prasad limited the shots to those with special risks like seniors, children, and adults with underlying conditions.
Prasad cited falling death/hospitalization rates and potential side effects as justification for the restrictions.
Top FDA leaders rarely overrule staff, and this action is considered controversial.
- Who
- FDA vaccine chief Dr. Vinay Prasad.
- What
- FDA vaccine chief restricted the approval of two COVID-19 vaccines.
- When
- Memos released Wednesday detailed the restrictions.
- Where
- The FDA
- Why
- Prasad cited lower death and hospitalization rates and potential side effects to justify the restrictions.
FDA Staff
FDA Vaccine Chief
Vaccine Availability
FDA Staff
COVID-19 vaccines should be available to everyone 12 and older, as the benefits outweigh the risks.
FDA Vaccine Chief
COVID-19 vaccines should be limited to those at higher risk, due to falling death and hospitalization rates and the possibility of side effects.
- Official
- Dr. Vinay Prasad
- Vaccines Affected
- Novavax and Moderna
- Original Recommendation
- Approved for 12+
- New Restriction
- Limited to high-risk groups
- Reason
- Falling death/hospitalization rates and potential side effects